Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05425316Completed

Speech in Hepatic Encephalopathy (HE)

Role: collaborator

NCT05563818Completed

Using Speech to Monitor Symptom Severity in Arabic Speaking Patients With Schizophrenia

Role: collaborator

NCT05601050Completed

Linguistic Predictors of Outcomes in Psychosis

Role: collaborator

NCT05601063Completed

Ascertaining Diagnosis Classification With Elicited Speech

Role: collaborator

NCT04851912Unknown

Speech-based Digital Biomarker for Psychiatric Disease

Role: lead

All 5 trials loaded